RU2010133892A - Гуманизированные моноклональные антитела против человеческого nkg2a - Google Patents
Гуманизированные моноклональные антитела против человеческого nkg2a Download PDFInfo
- Publication number
- RU2010133892A RU2010133892A RU2010133892/10A RU2010133892A RU2010133892A RU 2010133892 A RU2010133892 A RU 2010133892A RU 2010133892/10 A RU2010133892/10 A RU 2010133892/10A RU 2010133892 A RU2010133892 A RU 2010133892A RU 2010133892 A RU2010133892 A RU 2010133892A
- Authority
- RU
- Russia
- Prior art keywords
- antibody according
- antibody
- nkg2a
- amino acid
- human
- Prior art date
Links
- 101150069255 KLRC1 gene Proteins 0.000 title claims abstract 11
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 title claims abstract 11
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 title claims abstract 11
- 125000000539 amino acid group Chemical group 0.000 claims abstract 15
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 claims abstract 8
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 claims abstract 8
- 101100127356 Homo sapiens KLRD1 gene Proteins 0.000 claims abstract 7
- 108010001880 NK Cell Lectin-Like Receptor Subfamily C Proteins 0.000 claims abstract 7
- 102000000834 NK Cell Lectin-Like Receptor Subfamily C Human genes 0.000 claims abstract 7
- 230000035772 mutation Effects 0.000 claims abstract 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract 2
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 claims abstract 2
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 claims abstract 2
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims abstract 2
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims abstract 2
- 230000002401 inhibitory effect Effects 0.000 claims abstract 2
- 210000004698 lymphocyte Anatomy 0.000 claims abstract 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 150000001412 amines Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
1. Выделенное человеческое или гуманизированное антитело против NKG2A, которое ! (а) связывается с внеклеточной частью человеческого рецептора CD94/NKG2A, который экспрессируется на поверхности CD94/NKG2A-положительного лимфоцита, ! (б) снижает ингибиторную активность человеческого рецептора CD94/NKG2A и ! (в) не конкурирует с HLA-E за связывание с человеческим CD94/NKG2A рецептором. ! 2. Антитело по п.1, которое связывается с CD94/NKG2A с KD по меньшей мере в 100-раз ниже, чем для человеческого рецептора CD94/NKG2C. ! 3. Антитело по п.1, которое конкурирует с антителом Z199 за связывание с человеческим рецептором CD94/NKG2A. ! 4. Антитело по п.1, которое связывается с тем же эпитопом, что и антитело Z199. ! 5. Антитело по п.1, которое связывается с сегментом NKG2A (SEQ ID NO:11), содержащим аминокислотные остатки P94-N107, М189-Е197, или и те, и другие. ! 6. Антитело по п.1, которое связывается с эпитопом, содержащим аминокислотные остатки, выбранные из Р94, S95, Т96, L97, I98, Q99, R100, Н101, L106, М189, или Е197 NKG2A (SEQ ID NO:11), или любую их комбинацию. ! 7. Антитело по п.1, которое является гуманизированным антителом Z199. ! 8. Антитело по п.7, содержащее аминокислотные остатки Y31, L49 и Р94 вариабельного домена легкой цепи (VL) антитела Z199 (SEQ ID NO:2), и аминокислотные остатки Y57, Y102 и Р103 вариабельного домена тяжелой цепи (VH) антитела Z199 (SEQ ID NO:4). ! 9. Антитело по п.7, содержащее по меньшей мере одну обратную мутацию в последовательности каркасного участка VL или VH доменов. ! 10. Антитело по п.7, содержащее аминокислотный остаток Р45 VL домена Z199. ! 11. Антитело по п.7, содержащее аминокислотные остатки 24-33, 49-55 и 88-96 VL домена Z199 и аминокислотные остатки 31-35, 50-60, 62, 64, 66 и 99-108 VH домена Z199. ! 12. Антитело по п.7, содержащее серии (S), вставленный между амин
Claims (17)
1. Выделенное человеческое или гуманизированное антитело против NKG2A, которое
(а) связывается с внеклеточной частью человеческого рецептора CD94/NKG2A, который экспрессируется на поверхности CD94/NKG2A-положительного лимфоцита,
(б) снижает ингибиторную активность человеческого рецептора CD94/NKG2A и
(в) не конкурирует с HLA-E за связывание с человеческим CD94/NKG2A рецептором.
2. Антитело по п.1, которое связывается с CD94/NKG2A с KD по меньшей мере в 100-раз ниже, чем для человеческого рецептора CD94/NKG2C.
3. Антитело по п.1, которое конкурирует с антителом Z199 за связывание с человеческим рецептором CD94/NKG2A.
4. Антитело по п.1, которое связывается с тем же эпитопом, что и антитело Z199.
5. Антитело по п.1, которое связывается с сегментом NKG2A (SEQ ID NO:11), содержащим аминокислотные остатки P94-N107, М189-Е197, или и те, и другие.
6. Антитело по п.1, которое связывается с эпитопом, содержащим аминокислотные остатки, выбранные из Р94, S95, Т96, L97, I98, Q99, R100, Н101, L106, М189, или Е197 NKG2A (SEQ ID NO:11), или любую их комбинацию.
7. Антитело по п.1, которое является гуманизированным антителом Z199.
8. Антитело по п.7, содержащее аминокислотные остатки Y31, L49 и Р94 вариабельного домена легкой цепи (VL) антитела Z199 (SEQ ID NO:2), и аминокислотные остатки Y57, Y102 и Р103 вариабельного домена тяжелой цепи (VH) антитела Z199 (SEQ ID NO:4).
9. Антитело по п.7, содержащее по меньшей мере одну обратную мутацию в последовательности каркасного участка VL или VH доменов.
10. Антитело по п.7, содержащее аминокислотный остаток Р45 VL домена Z199.
11. Антитело по п.7, содержащее аминокислотные остатки 24-33, 49-55 и 88-96 VL домена Z199 и аминокислотные остатки 31-35, 50-60, 62, 64, 66 и 99-108 VH домена Z199.
12. Антитело по п.7, содержащее серии (S), вставленный между аминокислотными остатками 30 и 31 VL домена Z199.
13. Выделенное антитело, связывающееся с человеческим рецептором CD94/NKG2A и содержащее
(а) CDR-L1, содержащий SEQ ID NO:5;
(б) CDR-L2, содержащий SEQ ID NO:6;
(в) CDR-L3, содержащий SEQ ID NO:7;
(г) CDR-H1, содержащий SEQ ID NO:8;
(д) CDR-H2, содержащий SEQ ID NO:9;
(е) CDR-H3, содержащий SEQ ID NO:10;
(ж) человеческие каркасные участки VL и VH; и
(з) аминокислоту пролин (Р) в положении 46 по нумеарции Кабата (Kabat) в VL домене.
14. Антитело по п.13, содержащее константный домен человеческого lgG4, возможно, содержащий мутацию S241P.
15. Композиция, содержащая антитело по любому из предшествующих пунктов и фармацевтически приемлемый носитель, дилюент или наполнитель.
16. Антитело по любому из пп.1-14 для применения в лечении злокачественных неоплазий, вирусных инфекций, воспалительных нарушений и/или аутоиммунных заболеваний.
17. Способ получения антитела по любому из пп.1-14, включающий культивирование клеток-хозяев, трансформированных одним или более векторами, содержащими фрагмент нуклеиновой кислоты, кодирующей антитело, при условиях, которые способствуют экспрессии фрагмента (фрагментов) нуклеиновой кислоты и, возможно, выделение полученных антител.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08150601 | 2008-01-24 | ||
| EP08150601.6 | 2008-01-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010133892A true RU2010133892A (ru) | 2012-02-27 |
Family
ID=40566366
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010133892/10A RU2010133892A (ru) | 2008-01-24 | 2009-01-23 | Гуманизированные моноклональные антитела против человеческого nkg2a |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8796427B2 (ru) |
| EP (2) | EP2247619A1 (ru) |
| JP (1) | JP5774312B2 (ru) |
| KR (1) | KR20100110864A (ru) |
| CN (1) | CN101952317B (ru) |
| AU (1) | AU2009207644A1 (ru) |
| BR (1) | BRPI0908508A2 (ru) |
| CA (1) | CA2712220A1 (ru) |
| IL (1) | IL206639A0 (ru) |
| MX (1) | MX2010007935A (ru) |
| RU (1) | RU2010133892A (ru) |
| WO (1) | WO2009092805A1 (ru) |
| ZA (1) | ZA201004752B (ru) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3026063A1 (en) | 2004-12-28 | 2016-06-01 | Innate Pharma S.A. | Monoclonal antibodies against nkg2a |
| MX2008015830A (es) | 2006-06-30 | 2009-01-09 | Novo Nordisk As | Anticuerpos anti-nkg2a y usos de los mismos. |
| BRPI0908508A2 (pt) | 2008-01-24 | 2016-03-22 | Novo Nordisk As | anticorpo monoclonal nkg2a anti-humano humanizado |
| BR112012021576A2 (pt) | 2010-02-26 | 2016-10-25 | Novo Nordisk As | composições estáveis contendo anticorpo. |
| CN103635487B (zh) * | 2011-06-17 | 2016-10-12 | 诺沃—诺迪斯克有限公司 | 选择性消除侵蚀性细胞 |
| WO2015112836A2 (en) | 2014-01-24 | 2015-07-30 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Antibodies against f glycoprotein of hendra and nipah viruses |
| EP3186282A1 (en) | 2014-08-28 | 2017-07-05 | Academisch Ziekenhuis Leiden h.o.d.n. LUMC | Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations |
| CN113929782B (zh) * | 2014-09-16 | 2024-06-21 | 依奈特制药公司 | 对淋巴细胞中抑制途径的中和 |
| DK3193929T3 (da) * | 2014-09-16 | 2019-08-19 | Innate Pharma | Behandlingsregimer ved anvendelse af anti-nkg2a-antistoffer |
| RU2721271C2 (ru) | 2014-10-23 | 2020-05-18 | Иннейт Фарма | Лечение раковых заболеваний с применением анти-nkg2a средств |
| JP6895380B2 (ja) | 2015-02-06 | 2021-06-30 | ナショナル ユニバーシティ オブ シンガポール | 治療免疫細胞の有効性を改良するための方法 |
| KR20190080992A (ko) | 2015-05-21 | 2019-07-08 | 하푼 테라퓨틱스, 인크. | 삼중특이성 결합 단백질 및 사용 방법 |
| US10590198B2 (en) * | 2015-08-28 | 2020-03-17 | Alector Llc | Anti-siglec-7 antibodies and methods of use thereof |
| RS61901B1 (sr) | 2016-01-21 | 2021-06-30 | Innate Pharma | Neutralizacija inhibitornih puteva u limfocitima |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| US11440958B2 (en) | 2016-11-22 | 2022-09-13 | National University Of Singapore | Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies |
| SG10202107880XA (en) | 2017-05-12 | 2021-09-29 | Harpoon Therapeutics Inc | Mesothelin binding proteins |
| JP2020530291A (ja) | 2017-08-10 | 2020-10-22 | ナショナル ユニバーシティ オブ シンガポール | Ｔ細胞受容体欠損キメラ抗原受容体ｔ細胞およびその使用方法 |
| WO2019067425A1 (en) | 2017-09-26 | 2019-04-04 | The Trustees Of The University Of Pennsylvania | COMPOSITIONS AND METHODS FOR TREATING CARDIAC DISEASE BY REDIRECTED T-CELL IMMUNOTHERAPIES |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| PL3694529T3 (pl) | 2017-10-13 | 2024-12-16 | Harpoon Therapeutics, Inc. | Trójswoiste białka i sposoby zastosowania |
| EP3755371A4 (en) * | 2018-02-23 | 2021-11-24 | Abexxa Biologics, Inc. | ANTI-CANCER TREATMENT COMBINED WITH ANTI-CANCER AGENTS AND ANTIBODIES TARGETING A COMPLEX INCLUDING A NON-CLASSIC HLA-I AND A NEO-ANTIGEN |
| KR20200133233A (ko) | 2018-03-13 | 2020-11-26 | 이나뜨 파르마 | 두부경부암의 치료 |
| PE20210665A1 (es) | 2018-03-23 | 2021-03-31 | Bristol Myers Squibb Co | Anticuerpos contra mica y/o micb y sus usos |
| AU2019270277B9 (en) | 2018-05-15 | 2024-12-05 | Innate Pharma | Treatment of cancer |
| KR20210008408A (ko) | 2018-05-23 | 2021-01-21 | 싱가포르국립대학교 | T-세포 악성 종양의 면역요법을 위한 cd2 표면 발현 및 키메라 항원 수용체의 발현에 대한 차단 |
| CN119841953A (zh) | 2018-06-08 | 2025-04-18 | 艾利妥 | 抗siglec-7抗体及其使用方法 |
| WO2020035345A1 (en) | 2018-08-14 | 2020-02-20 | Innate Pharma | Treatment of colorectal cancer by a combination of an anti-mica antibody and an anti-nkg2a antibody |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| CN113286817B (zh) | 2018-09-25 | 2025-01-28 | 哈普恩治疗公司 | Dll3结合蛋白及使用方法 |
| EP3878869A4 (en) * | 2018-11-07 | 2023-04-19 | Shanghai Hyamab Biotech Co., Ltd. | NKG2A ANTIBODIES, METHOD OF PRODUCTION THEREOF AND USE THEREOF |
| US11274150B2 (en) * | 2018-11-16 | 2022-03-15 | Bristol-Myers Squibb Company | Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies |
| CN109833480B (zh) * | 2019-03-22 | 2021-09-07 | 中国科学院上海巴斯德研究所 | 靶向nk细胞免疫检查点治疗感染性疾病的方法 |
| JP2022528000A (ja) * | 2019-03-29 | 2022-06-07 | ドレン バイオ， インコーポレイテッド | 大顆粒リンパ球およびナチュラルキラー細胞レベルを低減する方法 |
| EP3965816A1 (en) | 2019-05-06 | 2022-03-16 | MedImmune Limited | Combination of monalizumab, durvalumab, chemotherapy and bevacizumab or cetuximab for the treatment of colorectal cancer |
| EP3977132A1 (en) | 2019-05-30 | 2022-04-06 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
| CN114174538A (zh) | 2019-05-30 | 2022-03-11 | 百时美施贵宝公司 | 适合于免疫肿瘤学疗法的多肿瘤基因特征 |
| KR20220016155A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법 |
| US20220259290A1 (en) * | 2019-07-24 | 2022-08-18 | Japan Science And Technology Agency | Innovative production technique for antibody-enzyme |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| CN110575537A (zh) * | 2019-09-06 | 2019-12-17 | 刘慧宁 | Dc疫苗和nkg2a拮抗剂的组合物及在抗乳腺癌或肝癌中的应用 |
| CN110585427B (zh) * | 2019-09-06 | 2023-06-06 | 刘慧宁 | 提高机体免疫力的组合物及在抗成人t细胞白血病或鼻咽癌中的应用 |
| AU2020353000A1 (en) | 2019-09-23 | 2022-04-07 | The Trustees Of The University Of Pennsylvania | Disrupting tumor tissues by targeting fibroblast activation protein (FAP) |
| CN114761036B (zh) | 2019-09-23 | 2025-09-30 | 宾夕法尼亚大学董事会 | 与小鼠和人成纤维细胞激活蛋白(fap)交叉反应的抗犬成纤维细胞激活蛋白单克隆抗体 |
| CN113583127A (zh) * | 2020-04-30 | 2021-11-02 | 迈威(上海)生物科技股份有限公司 | 一种靶向nkg2a和pd-l1的双特异性抗体及应用 |
| KR20230010228A (ko) * | 2020-05-08 | 2023-01-18 | 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 | 자연 살해 세포를 표적으로 하는 키메라 항원 수용체 (cars) |
| CN113801238A (zh) * | 2020-06-11 | 2021-12-17 | 南京北恒生物科技有限公司 | 表达nk抑制性分子的工程化免疫细胞及其用途 |
| KR20230035576A (ko) | 2020-07-07 | 2023-03-14 | 비온테크 에스이 | Hpv 양성 암 치료용 rna |
| CA3190660A1 (en) | 2020-08-31 | 2022-03-03 | George C. Lee | Cell localization signature and immunotherapy |
| US11795228B2 (en) | 2020-09-30 | 2023-10-24 | Dren Bio, Inc. | Anti-CD94 antibodies and methods of use thereof |
| AU2021357841A1 (en) | 2020-10-08 | 2023-06-15 | Affimed Gmbh | Trispecific binders |
| CN114524876B (zh) * | 2020-11-23 | 2025-12-05 | 南京北恒生物科技有限公司 | 靶向nkg2a的抗体及其用途 |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| SMT202500208T1 (it) | 2020-12-28 | 2025-07-22 | Bristol Myers Squibb Co | Composizioni anticorpali e metodi per il loro uso |
| CA3196999A1 (en) | 2020-12-28 | 2022-07-07 | Masano HUANG | Methods of treating tumors |
| WO2022179620A1 (zh) * | 2021-02-25 | 2022-09-01 | 克莱格医学有限公司 | Cd94工程化细胞及其组合物 |
| EP4314068A1 (en) | 2021-04-02 | 2024-02-07 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| EP4347651A1 (en) | 2021-06-01 | 2024-04-10 | Les Laboratoires Servier | Anti-nkg2a antibodies and compositions |
| EP4512826A3 (en) | 2021-07-09 | 2025-04-02 | Luxembourg Institute Of Health (LIH) | Dimeric protein complexes and uses thereof |
| AU2022312698A1 (en) | 2021-07-13 | 2024-01-25 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| AU2022320948A1 (en) | 2021-07-30 | 2024-01-18 | Affimed Gmbh | Duplexbodies |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| KR20240159621A (ko) | 2022-03-18 | 2024-11-05 | 브리스톨-마이어스 스큅 컴퍼니 | 폴리펩티드를 단리하는 방법 |
| WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| AU2023342647A1 (en) | 2022-09-15 | 2025-02-20 | Avidicure Ip B.V. | Multispecific antigen binding proteins for tumor-targeting of nk cells and use thereof |
| CN119866349A (zh) * | 2022-09-16 | 2025-04-22 | 北京三诺佳邑生物技术有限责任公司 | 特异性识别nkg2a的抗体及其应用 |
| CN115957319B (zh) * | 2022-10-14 | 2023-06-30 | 北京东方百泰生物科技股份有限公司 | 一种抗nkg2a单克隆抗体的注射制剂 |
| CN120418289A (zh) | 2022-12-14 | 2025-08-01 | 安斯泰来制药欧洲有限公司 | 结合cldn18.2和cd3的双特异性结合剂与免疫检查点抑制剂的联合疗法 |
| CN116178551A (zh) * | 2022-12-29 | 2023-05-30 | 北京东方百泰生物科技股份有限公司 | 一种抗nkg2a单克隆抗体的纯化方法 |
| EP4663762A2 (en) * | 2023-03-02 | 2025-12-17 | HongKong Bioheng Biotech Limited | Immune rejection-resistant engineered cell |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| WO2025038763A1 (en) | 2023-08-15 | 2025-02-20 | Bristol-Myers Squibb Company | Ceramic hydroxyapatite chromatography flow through method |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025121445A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| US20250215087A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg depleting agent |
| WO2025166550A1 (zh) * | 2024-02-06 | 2025-08-14 | 香港北恒生物科技有限公司 | 工程化细胞及其用途 |
| WO2025168052A1 (en) * | 2024-02-08 | 2025-08-14 | Hanx Biopharmaceuticals, (Wuhan) Ltd. | Nkg2a/cd94-targeting antibodies and uses thereof |
| WO2025191133A1 (en) | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Il-21 muteins, fusion proteins comprising the same and uses thereof |
| WO2025191136A1 (en) | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4609546A (en) | 1982-06-24 | 1986-09-02 | Japan Chemical Research Co., Ltd. | Long-acting composition |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| DE68925971T2 (de) | 1988-09-23 | 1996-09-05 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| JPH03112486A (ja) | 1989-09-22 | 1991-05-14 | Olympus Optical Co Ltd | Ｈｌａ―ｂ３５遺伝子およびｄｎａプローブ並びに形質転換細胞 |
| JPH03112485A (ja) | 1989-09-22 | 1991-05-14 | Olympus Optical Co Ltd | Ｈｌａ―ｃ遺伝子およびｄｎａプローブ並びに形質転換細胞 |
| JPH03112487A (ja) | 1989-09-22 | 1991-05-14 | Olympus Optical Co Ltd | ＨＬＡ―Ｂｗ５３遺伝子およびＤＮＡプローブ並びに形質転換細胞 |
| US6750325B1 (en) | 1989-12-21 | 2004-06-15 | Celltech R&D Limited | CD3 specific recombinant antibody |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| JPH03112484U (ru) | 1990-03-02 | 1991-11-18 | ||
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| US5165424A (en) | 1990-08-09 | 1992-11-24 | Silverman Harvey N | Method and system for whitening teeth |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| US6797492B2 (en) | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| US5869619A (en) | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
| ATE249840T1 (de) | 1991-12-13 | 2003-10-15 | Xoma Corp | Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung |
| US5777085A (en) | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
| DE69334255D1 (de) | 1992-02-06 | 2009-02-12 | Novartis Vaccines & Diagnostic | Marker für Krebs und biosynthetisches Bindeprotein dafür |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5489525A (en) * | 1992-10-08 | 1996-02-06 | The United States Of America As Represented By The Department Of Health And Human Services | Monoclonal antibodies to prostate cells |
| DE69303494T2 (de) | 1992-11-13 | 1997-01-16 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| CU22615A1 (es) | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
| HU221385B1 (en) * | 1994-07-13 | 2002-09-28 | Chugai Pharmaceutical Co Ltd | Reconstituted human antibody against human interleukin-8 |
| US5876950A (en) * | 1995-01-26 | 1999-03-02 | Bristol-Myers Squibb Company | Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5697151A (en) | 1995-08-07 | 1997-12-16 | General Electric Company | Method for repairing partitions of a turbine diaphragm |
| CA2253904A1 (en) | 1996-05-03 | 1997-11-13 | Immunomedics, Inc. | Targeted combination immunotherapy of cancer |
| WO1998049198A1 (en) | 1997-04-30 | 1998-11-05 | Enzon, Inc. | Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof |
| ATE319745T1 (de) | 1997-05-21 | 2006-03-15 | Biovation Ltd | Verfahren zur herstellung von nicht-immunogenen proteinen |
| GB9725764D0 (en) | 1997-12-04 | 1998-02-04 | Isis Innovation | HLA-E binding |
| IL151873A0 (en) | 2000-03-24 | 2003-04-10 | Micromet Ag | Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| US6999941B1 (en) | 2000-07-11 | 2006-02-14 | Amazon.Com, Inc. | Providing gift clustering functionality to assist a user in ordering multiple items for a recipient |
| AU8470301A (en) | 2000-08-03 | 2002-02-18 | Wim-Van Schooten | Production of humanized antibodies in transgenic animals |
| EP1343822B1 (en) | 2000-12-18 | 2012-05-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Means for the diagnosis and therapy of ctcl |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030095965A1 (en) | 2001-05-02 | 2003-05-22 | Katrien Van Beneden | Antibodies to Ly49E and CD94/NKG2 receptors |
| AU2002325333B2 (en) | 2001-07-19 | 2008-04-03 | Innate Pharma | NTB-A, a surface molecule involved in natural killer cells activity |
| KR20040041575A (ko) | 2001-07-31 | 2004-05-17 | 칼 페터 쇠더스트룀 | 면역반응의 모듈화 조성물 및 모듈화 방법 |
| AU2003233894A1 (en) | 2002-05-13 | 2003-11-11 | Envirotech Products Limited | Tank valve testing method |
| WO2003101485A1 (en) | 2002-05-30 | 2003-12-11 | Macrogenics, Inc. | Cd16a binding proteins and use for the treatment of immune disorders |
| AU2003244817B2 (en) | 2002-06-28 | 2010-08-26 | Domantis Limited | Antigen-binding immunoglobulin single variable domains and dual-specific constructs |
| CN1751236A (zh) | 2002-12-16 | 2006-03-22 | 健泰科生物技术公司 | 表达人cd20的转基因小鼠 |
| CN103833854B (zh) * | 2002-12-16 | 2017-12-12 | 健泰科生物技术公司 | 免疫球蛋白变体及其用途 |
| LT1648507T (lt) * | 2003-07-24 | 2017-04-25 | Innate Pharma S.A. | Būdai ir kompozicijos, skirti terapinių antikūnų efektyvumo padidinimui, naudojant nk ląsteles stiprinančius junginius |
| WO2005040219A1 (en) | 2003-10-28 | 2005-05-06 | Novo Nordisk A/S | Laminin-5 gamma2-binding peptides, related compositions, and use thereof |
| WO2005105849A1 (en) | 2004-04-30 | 2005-11-10 | Innate Pharma | Compositions and methods for treating proliferative disorders such as nk-type ldgl |
| CN101107269B (zh) | 2004-12-28 | 2012-10-31 | 依奈特制药公司 | 抗nkg2a的单克隆抗体 |
| EP3026063A1 (en) * | 2004-12-28 | 2016-06-01 | Innate Pharma S.A. | Monoclonal antibodies against nkg2a |
| US9447185B2 (en) * | 2005-10-14 | 2016-09-20 | Innate Pharma, S.A. | Compositions and methods for treating proliferative disorders |
| MX2008015830A (es) * | 2006-06-30 | 2009-01-09 | Novo Nordisk As | Anticuerpos anti-nkg2a y usos de los mismos. |
| BRPI0908508A2 (pt) | 2008-01-24 | 2016-03-22 | Novo Nordisk As | anticorpo monoclonal nkg2a anti-humano humanizado |
-
2009
- 2009-01-23 BR BRPI0908508A patent/BRPI0908508A2/pt not_active IP Right Cessation
- 2009-01-23 KR KR1020107017547A patent/KR20100110864A/ko not_active Withdrawn
- 2009-01-23 EP EP09704675A patent/EP2247619A1/en not_active Ceased
- 2009-01-23 RU RU2010133892/10A patent/RU2010133892A/ru unknown
- 2009-01-23 JP JP2010543510A patent/JP5774312B2/ja active Active
- 2009-01-23 CN CN200980102632.6A patent/CN101952317B/zh active Active
- 2009-01-23 AU AU2009207644A patent/AU2009207644A1/en not_active Withdrawn
- 2009-01-23 WO PCT/EP2009/050795 patent/WO2009092805A1/en not_active Ceased
- 2009-01-23 EP EP13165207.5A patent/EP2628753A1/en not_active Withdrawn
- 2009-01-23 MX MX2010007935A patent/MX2010007935A/es not_active Application Discontinuation
- 2009-01-23 CA CA2712220A patent/CA2712220A1/en not_active Abandoned
- 2009-01-23 US US12/811,990 patent/US8796427B2/en active Active
-
2010
- 2010-06-27 IL IL206639A patent/IL206639A0/en unknown
- 2010-07-06 ZA ZA2010/04752A patent/ZA201004752B/en unknown
-
2014
- 2014-08-01 US US14/449,346 patent/US9422368B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009092805A1 (en) | 2009-07-30 |
| MX2010007935A (es) | 2010-08-23 |
| CA2712220A1 (en) | 2009-07-30 |
| AU2009207644A1 (en) | 2009-07-30 |
| CN101952317A (zh) | 2011-01-19 |
| US9422368B2 (en) | 2016-08-23 |
| EP2247619A1 (en) | 2010-11-10 |
| US20140341896A1 (en) | 2014-11-20 |
| US20110052606A1 (en) | 2011-03-03 |
| KR20100110864A (ko) | 2010-10-13 |
| US8796427B2 (en) | 2014-08-05 |
| CN101952317B (zh) | 2015-07-22 |
| ZA201004752B (en) | 2011-04-28 |
| EP2628753A1 (en) | 2013-08-21 |
| BRPI0908508A2 (pt) | 2016-03-22 |
| JP5774312B2 (ja) | 2015-09-09 |
| IL206639A0 (en) | 2010-12-30 |
| JP2011510047A (ja) | 2011-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010133892A (ru) | Гуманизированные моноклональные антитела против человеческого nkg2a | |
| RU2012142311A (ru) | Интерлейкин-13-связывающие белки | |
| RU2008149918A (ru) | Антитела к nkg2a и их применения | |
| RU2017110044A (ru) | Антитела и химерные антигенные рецепторы, специфичные к cd19 | |
| RU2013125459A (ru) | АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met | |
| JP2020079252A5 (ru) | ||
| JP2020528768A5 (ru) | ||
| RU2012147286A (ru) | Гуманизированные антитела к фактору d и их применения | |
| RU2011150916A (ru) | Антитела против vegf и их применения | |
| RU2015115956A (ru) | Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения | |
| US20200347130A1 (en) | CD96 Antibody, Antigen-Binding Fragment and Pharmaceutical use Thereof | |
| RU2015118180A (ru) | Антитела к бета-амилоиду | |
| PE20091474A1 (es) | Anticuerpos monoclonales contra la proteina rgm a y sus usos | |
| RU2008126242A (ru) | Антитела против глобуломера а бета, их антигенсвязывающие части, соответствующие гибридомы, нуклеиновые кислоты, векторы, клетки-хозяева, способы получения указанных антител, композиции, содержащие указанные антитела, применения указанных антител и способы использования указанных антител | |
| RU2014151788A (ru) | Молекула, специфически связывающаяся с rsv | |
| JP2017526370A5 (ru) | ||
| RU2009136913A (ru) | Биспецифические связывающие агенты с межвидовой специфичностью | |
| JP2013545738A5 (ru) | ||
| JP2018508188A5 (ru) | ||
| JP2016512551A5 (ru) | ||
| RU2012142230A (ru) | Антитела против csf-1r человека и их применение | |
| RU2012130840A (ru) | Соединения | |
| JP2006506955A5 (ru) | ||
| JP2014509861A5 (ru) | ||
| UA108466C2 (en) | Antibody antagonises c-Met |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA91 | Application withdrawn (on applicant's request) |
Effective date: 20120618 |